PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 160 participants.

Also called NCT04971720

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose other
Phase
Phase 2/3
Enrolled
  • 160 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04971720
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT04971720. Randomized; quadruple masking; primary purpose other. Start 2022-02-18 (actual); primary completion 2027-01-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis
Acronym
PRECISION-BP
Condition
Obesity
Condition
Cardiovascular Diseases
Condition
Hypertension
Condition
Nocturnal Blood Pressure
Condition
Renin-Angiotensin-Aldosterone System
Intervention (Drug)
Sacubitril-Valsartan 49 Mg-51 Mg Oral Tablet
Intervention (Drug)
Valsartan 80 mg Oral Tablet
Lead sponsor
University of Alabama at Birmingham (class: other)
Collaborator
National Heart, Lung, and Blood Institute (NHLBI) (class: US National Institutes of Health)

Record details

Record id
cardio:ct-nct04971720
Content hash
8399c0dd92d4f8d3c43c3cf3f9667c0f2b5171f2bf09415554eb825d48231b96